Ourself

Ourself is a New York-based biotechnology company that provides a range of at-home, sub-topical skincare for the B2B and B2C markets. The company’s skincare range leverages a portfolio of peptides, called Intides, delivered sub-topically to the layer of skin that needs it most through a multiphasic vesicle made from natural resources like collagen and elastin. Ourself’s products offer an alternative to clinical or dermatological procedures like injectables and clinical peels and lasers. The company’s peptide-based products can treat various conditions including hyperpigmentation, lines and wrinkles, dryness, and loss of volume.

Key customers and partnerships

Ourself initially grew its B2C base through partnerships with retail players like Violet Grey, Bluemercury, Moda Operandi, Nordstrom, and Ever/Body. In May 2023, Ourself also announced plans to launch with premier retail and spa partners to broaden market reach.

Funding and financials

As of February 2023, Ourself had received USD 30 million in funding for its at-home biotech alternatives to clinical products.

Key competitors: None comparable (the only biotech company in the hub that offers sub-topical skincare).